Author's response to reviews

Title: Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in glucose-6-phosphate dehydrogenase deficient and normal Cambodians.

Authors:

Sim Kheng (khengsim@gmail.com)
Muth Sinoun (sinuonn@gmail.com)
Walter RJ Taylor (bob@tropmedres.ac)
Narran Tops (tops@wipro.who.int)
Khem Kosal (khem_monykosal@yahoo.com)
Khon Sothea (khonsothea44@gmail.com)
Phum Souy (phumsouy@gmail.com)
Saorin Kim (ksaorin@pasteur-kh.org)
Chuor M Char (mengchuor@gmail.com)
Chan Vanna (chanvanna@hotmail.com)
Po Ly (polyteng168@gmail.com)
Pascal Ringwald (ringwaldp@who.int)
Virak Khieu (virak.khieu@gmail.com)
Alexandra Kerleguer (akerleguer@pasteur-kh.org)
Pety Tor (pety@pasteur-kh.org)
John K Baird (jkevinbaird@yahoo.com)
Steven Bjorge (steven_bjorge@hotmail.com)
Didier Menard (dmenard@pasteur-kh.org)
Eva Christophel (ChristophelE@wpro.who.int)

Version: 4
Date: 24 July 2015

Author's response to reviews:

Dear Editor,

we have made all the changes requested by the reviewer. These are:
corrected the legends and amended text as follows:

Most P. vivax strains in SE
in severely deficient, Cambodian
tafenoquine as antirelapse treatment to achieve P. vivax radical cure
without the need for testing for G6PDd.

We have now provided all the details relating to the drug purchase:

Primaquine was first obtained from Cipla, India, and was QC`ed satisfactorily by
an external laboratory. Towards study end, primaquine was obtained from the
Government Pharmaceutical Organisation, Thailand, but not sent for external
QC.
removed the genes